These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 1483316)
1. The effect of intravenous immunoglobulin on lymphocyte populations in children with Kawasaki syndrome. Saulsbury FT Clin Exp Rheumatol; 1992; 10(6):617-20. PubMed ID: 1483316 [TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease. Ye Q; Gong FQ; Shang SQ; Hu J Clin Immunol; 2016 Oct; 171():25-31. PubMed ID: 27519954 [TBL] [Abstract][Full Text] [Related]
3. Relationship between T-cell HLA-DR expression and intravenous immunoglobulin treatment response in Kawasaki disease. Wakiguchi H; Hasegawa S; Suzuki Y; Kudo K; Ichiyama T Pediatr Res; 2015 Apr; 77(4):536-40. PubMed ID: 25580740 [TBL] [Abstract][Full Text] [Related]
4. Effects of intravenous immune globulin on the peripheral lymphocyte phenotypes in Kawasaki disease. Lee HK; Kim DS; Noh GW; Lee KY Yonsei Med J; 1996 Oct; 37(5):357-63. PubMed ID: 8997168 [TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease. Ichiyama T; Ueno Y; Hasegawa M; Ishikawa Y; Matsubara T; Furukawa S Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393 [TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous immunoglobulin on inhibiting peripheral blood lymphocyte apoptosis in acute Kawasaki disease. Yi QJ; Li CR; Yang XQ Acta Paediatr; 2001 Jun; 90(6):623-7. PubMed ID: 11440093 [TBL] [Abstract][Full Text] [Related]
9. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study]. Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453 [TBL] [Abstract][Full Text] [Related]
10. Immunoregulatory changes in Kawasaki disease. Jason J; Gregg L; Han A; Hu A; Inge KL; Eick A; Tham I; Campbell R Clin Immunol Immunopathol; 1997 Sep; 84(3):296-306. PubMed ID: 9281389 [TBL] [Abstract][Full Text] [Related]
11. [Changes in CD69, CD25 and HLA-DR expressions in peripheral blood T cells in Kawasaki disease]. Zhang YY; Huang XM; Kang ML; Gong FQ; Qian BQ Zhonghua Er Ke Za Zhi; 2006 May; 44(5):329-32. PubMed ID: 16780706 [TBL] [Abstract][Full Text] [Related]
12. Changes in Peripheral Blood Neutrophils, Lymphocytes and IL-10 in Children with Kawasaki Disease from Different Age Groups Undergoing Intravenous Immunoglobulin: A Retrospective Study. Zhang C; Zhang X; Shen J; Lu X; Zhang J; Chen S Mediators Inflamm; 2020; 2020():5213451. PubMed ID: 33293897 [TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin therapy in Kawasaki syndrome and RSV prophylaxis. Meissner HC; Leung DY Front Biosci; 1996 Aug; 1():e55-64. PubMed ID: 9159245 [TBL] [Abstract][Full Text] [Related]
14. Predicting IVIG resistance in UK Kawasaki disease. Davies S; Sutton N; Blackstock S; Gormley S; Hoggart CJ; Levin M; Herberg JA Arch Dis Child; 2015 Apr; 100(4):366-8. PubMed ID: 25670405 [TBL] [Abstract][Full Text] [Related]
15. [Plasma exchange therapy for Kawasaki disease refractory to intravenous immunoglobulin]. Mori M Nihon Rinsho; 2008 Feb; 66(2):349-54. PubMed ID: 18260334 [TBL] [Abstract][Full Text] [Related]
16. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Guo MM; Tseng WN; Ko CH; Pan HM; Hsieh KS; Kuo HC Allergy; 2015 Mar; 70(3):310-8. PubMed ID: 25585854 [TBL] [Abstract][Full Text] [Related]
17. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. Gupta M; Noel GJ; Schaefer M; Friedman D; Bussel J; Johann-Liang R J Clin Immunol; 2001 May; 21(3):193-9. PubMed ID: 11403226 [TBL] [Abstract][Full Text] [Related]
18. Exploring the genes associated with the response to intravenous immunoglobulin in patients with Kawasaki disease using DNA microarray analysis. Xing Y; Wang H; Liu X; Yu X; Chen R; Wang C; Yu X; Sun L Exp Mol Pathol; 2015 Feb; 98(1):7-12. PubMed ID: 25449331 [TBL] [Abstract][Full Text] [Related]
19. The Combined Usefulness of the Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Predicting Intravenous Immunoglobulin Resistance with Kawasaki Disease. Kawamura Y; Takeshita S; Kanai T; Yoshida Y; Nonoyama S J Pediatr; 2016 Nov; 178():281-284.e1. PubMed ID: 27526622 [TBL] [Abstract][Full Text] [Related]
20. Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease. Sakurai Y; Takatsuka H; Onaka M; Takada M; Nishino M Int Arch Allergy Immunol; 2014; 165(2):111-8. PubMed ID: 25401215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]